Bremelanotide (PT-141) Approved by FDA for Treating Low Sexual Desire in Women

PT-141 (Bremelanotide) is one of the few peptides with full FDA approval, and it works through a completely different mechanism than previous approaches to sexual dysfunction. Instead of targeting blood flow like Viagra, it acts on melanocortin receptors in the brain—essentially modulating the neural pathways that regulate desire itself. This matters because for many people, especially women, sexual dysfunction isn't mechanical; it's neurological and hormonal. The FDA approval means there's robust clinical data proving safety and efficacy in thousands of patients, not just animal models or anecdotal reports. What's particularly interesting is that PT-141 was originally developed from Melanotan II (a tanning peptide) when researchers noticed sexual arousal as a 'side effect'—a reminder that melanocortin signaling influences multiple physiological systems including sexual function, appetite, and inflammation.

Bremelanotide's path to approval was long and unconventional. Initially developed as a nasal spray, it was reformulated as a subcutaneous injection after concerns about blood pressure effects. The FDA approval in 2019 (marketed as Vyleesi) was significant because it was only the second drug ever approved for female sexual desire disorder, and the first with a non-hormonal mechanism. The clinical trials included over 1,200 women and demonstrated consistent improvements in desire and satisfying sexual events. The peptide's mechanism—activating MC3R and MC4R melanocortin receptors in the hypothalamus—represents a fundamentally different approach to sexual wellness, targeting central nervous system pathways rather than peripheral vascular effects. While approved specifically for premenopausal women with HSDD, the underlying neurobiology of melanocortin signaling in sexual arousal is relevant to broader sexual wellness research.

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial